BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32397827)

  • 1. Design, synthesis, chemical characterization, biological evaluation, and docking study of new 1,3,4-oxadiazole homonucleoside analogs.
    El Mansouri AE; Maatallah M; Ait Benhassou H; Moumen A; Mehdi A; Snoeck R; Andrei G; Zahouily M; Lazrek HB
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(8):1088-1107. PubMed ID: 32397827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biological evaluation and molecular docking of new 1,3,4-oxadiazole homonucleosides and their double-headed analogs as antitumor agents.
    El Mansouri AE; Oubella A; Mehdi A; AitItto MY; Zahouily M; Morjani H; Lazrek HB
    Bioorg Chem; 2021 Mar; 108():104558. PubMed ID: 33358270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel furo[2,3-d]pyrimidin-2-one-1,3,4-oxadiazole hybrid derivatives as dual antiviral and anticancer agents that induce apoptosis.
    El Mansouri AE; Oubella A; Dânoun K; Ahmad M; Neyts J; Jochmans D; Snoeck R; Andrei G; Morjani H; Zahouily M; Lazrek HB
    Arch Pharm (Weinheim); 2021 Oct; 354(10):e2100146. PubMed ID: 34128255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
    Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
    Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing of acyclonucleoside analogues tethered 1,2,4-triazole as anticancer agents with dual epidermal growth factor receptor kinase and microtubule inhibitors.
    Aouad MR; Al-Mohammadi HM; Al-Blewi FF; Ihmaid S; Elbadawy HM; Althagfan SS; Rezki N
    Bioorg Chem; 2020 Jan; 94():103446. PubMed ID: 31791685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
    Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
    Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
    Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
    Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
    Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues.
    Ahsan MJ; Choupra A; Sharma RK; Jadav SS; Padmaja P; Hassan MZ; Al-Tamimi ABS; Geesi MH; Bakht MA
    Anticancer Agents Med Chem; 2018; 18(1):121-138. PubMed ID: 28425854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, biological evaluation and molecular docking of new uracil analogs-1,2,4-oxadiazole hybrids as potential anticancer agents.
    El Mansouri AE; Oubella A; Maatallah M; AitItto MY; Zahouily M; Morjani H; Lazrek HB
    Bioorg Med Chem Lett; 2020 Oct; 30(19):127438. PubMed ID: 32736079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, modelling studies and biological evaluation of 1,3,4-oxadiazole derivatives as potent anticancer agents targeting thymidine phosphorylase enzyme.
    Bajaj S; Kumar MS; Tinwala H; Yc M
    Bioorg Chem; 2021 Jun; 111():104873. PubMed ID: 33845381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
    Dokla EME; Fang CS; Abouzid KAM; Chen CS
    Eur J Med Chem; 2019 Nov; 182():111607. PubMed ID: 31446247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and
    Hagras M; Saleh MA; Ezz Eldin RR; Abuelkhir AA; Khidr EG; El-Husseiny AA; El-Mahdy HA; Elkaeed EB; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):380-396. PubMed ID: 34923885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.